Salvia Injection Combined With Atorvastatin Treatment Of Coronary Slow Flow Of Clinical Review

Background:Coronary slow flow phenomenon (CSFP), the concept of the first put forward by professor Tamble in 1972, but this kind of phenomenon in the late 1990 s was Mangieri and Diver scholars attention:in the part during coronary angiography in patients with chest pain, although no significant coronary artery lesions (excluding coronary artery spasm, myocardial bridge, cystic expansion, PCI postoperative coronary arteries and the other by heart valve disease, connective tissue disease caused by coronary obstructive lesions), but distal coronary blood perfusion, the phenomenon of the delay. As coronary angiography examination in recent years in our country were extensively developed, and this phenomenon has gradually aroused the concern heart the depth of the clinicians. In our hospital from 2010 to 2014 for part of unstable angina and acute myocardial infarction, stable angina patients found in imaging examination, higher incidence of coronary artery blood flow delay phenomenon, caused the patient’s normal life and work serious impact, but the mechanism of this kind of phenomenon there is no accurate conclusion. Atorvastatin calcium, which is hydroxymethyl glutaryl coenzyme phenol A (HMG-CoA) reductase inhibition agent, and as a rate-limiting enzyme of cholesterol synthesis in liver, can inhibit the biosynthesis of cholesterol in the liver, lower blood cholesterol and lipoprotein levels and that it can induce significant and sustained hepatic LDL receptors on the cell surface to generate, thereby increasing serum LDL uptake and metabolism in the decomposition and removal. Clinical studies have shown that the use of atorvastatin alone poor treatment of coronary slow flow effect. On the basis of this treatment, the use of salvianolate injection for treatment of coronary slow flow. Salvianolate preparation process is the active ingredient of modern medicine concentrated Salvia, Salvia magnesium acetate as the main component of polyphenols salts, salvia is the most important and effective active ingredients, it can play a protective through a variety of mechanisms and pathways the role of the cardiovascular system. This study focuses on the salvia injection combined with atorvastatin treatment of coronary slow flow of clinical efficacy and safety, aims for the clinical treatment of coronary slow flow provides an effective method.Objective:To investigate salvia injection combined with atorvastatin treatment of coronary slow flow of clinical efficacy and safety.Methods:80 cases of patients with coronary slow flow of 1:1 ratio were randomly divided into control group and observation group, the 40 cases. The control group using only atorvastatin treatment, observation group salvianolate injection combined treatment on this basis. Comparison of two clinical efficacy, two changes of lipid levels before and after treatment, both groups before and after treatment IMT and plaque area, the onset of symptoms before and after treatment frequency and average duration of the index levels of vascular endothelial function before and after treatment, both groups blood uric acid levels before and after treatment, after treatment, quality of life and incidence of adverse reactions.Result:(1) After treatment, the total efficiency of the clinical observation group was significantly higher, the difference was statistically significant (P<0.05);(2) the onset of symptoms after treatment, the frequency and average duration of treatment was significantly ago, the differences were statistically significant (P<0.05), and the observation group therapy after the onset of symptoms frequency and average duration was significantly lower than the control group after (P<0.05);(3) there was no statistically significant difference control LVEF ultrasound results before and after the treatment (P>0.05), and LVEF ultrasound results after treatment of observation group were significantly greater than the control group (P<0.05), myocardial perfusion improved markedly(4) differences in lipid levels before and after treatment in the control group was not statistically significant (P> 0.05), but the observation group after treatment TC and LDL-C levels were statistically significant differences (P<0.05), and the two groups after treatment and TC LDL-C levels were statistically significant differences (P<0.05);Before and after(5) the level of the two groups before and after treatment NID DO and no statistically significant difference (P> 0.05), but FMD levels between the two groups before and after treatment were statistically significant (P<0.05),;(6) Serum Hs-CRP levels were statistically significant differences (P around after treatment<0.05), but after treatment serum Hs-CRP levels showed no significant difference (P> 0.05);Before and after(7) in the control group had no significant difference UA level (P> 0.05), UA levels observed group differences before and after treatment was statistically significant (P<0.05), and UA levels were observed after treatment group were significantly lower than the control group after (P <0.05);(8) According to the SF-36 quality of life assessment scale, the observation group after treatment quality of life scale each dimension (physical function, mental function, bodily pain, general health, vitality, social function, role emotional, mental health, physical-related life Quality, psychological related quality of life) scores were significantly higher after treatment, the differences were statistically significant (P<0.05);(9) for 8 weeks atorvastatin group found two cases of patients with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased more than two times the upper limit of normal, be deactivated atorvastatin tablets treatment, disable A Torvald statin piece two weeks after his review, the patients were normal ALT and AST. Atorvastatin group did not find myalgia, creatine kinase (CK) and creatine kinase MB (CKMB) increased the patient. Observation group found no drug allergies, ALT, AST and CK, CKMB increased adverse drug reactions, such as the patient.Conclusion:Salvia injection combined with the clinical efficacy of atorvastatin treatment of coronary slow flow is more significant, and high security, can be used as an effective treatment method for the clinical treatment of coronary slow flow, thus providing for the clinical treatment based methodology. of the disease...